article

Drug Target Review – Issue #4 2017

Posted: 5 December 2017 | | No comments yet

Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.

  • FOREWORD: Artificial intelligence in drug discover: how long before we see the real impact?
    Richard Goodwin, Principal Scientist, AstraZeneca
  • APPLICATION NOTE: Performing NanoBRET with the Varioskan LUX multimode reader
    Thermo Fisher Scientific
  • IN-DEPTH FOCUS: Screening
  • APPLICATION NOTE: Screening for inhibitors of PD-1 and PD-L1 binding with AlphaLISA technology
    PerkinElmer
  • APPLICATION NOTE: Next-generation sequencing sample preparation on the Thermo Scientific KingFisher platform
    Thermo Fisher Scientific
  • PROTEOMICS: Proteogenomics research – on the frontier of precision medicine
    Alicia Landeira, Rodrigo Garcia-Valiente, Maria Gonzalez-Gonzalez, Javier Carabias, Jonatan García, Rafael Góngora, Paula Diez and Manuel Fuentes, University of Salamanca
  • IN-DEPTH FOCUS: Hit to lead
  • METABOLIC DISEASE: Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases
    Carmen Lorenz, Max Delbrück Center for Molecular Medicine (MDC) and Berlin Institute of Health (BIH); Gizem Inak and Alessandro Prigione, Max Delbrück Center for Molecular Medicine (MDC)
  • IN-DEPTH FOCUS: Informatics

 

 

 

The digital version of issue #4 2017 is restricted to logged-in members. Login or subscribe free to read it.


Send this to a friend